Diagnostic Accuracy of NS1 ELISA and Lateral Flow Rapid Tests for Dengue Sensitivity, Specificity and Relationship to Viraemia and Antibody Responses by Ty Hang, Vu et al.
Diagnostic Accuracy of NS1 ELISA and Lateral Flow Rapid
Tests for Dengue Sensitivity, Specificity and Relationship
to Viraemia and Antibody Responses
Vu Ty Hang
1, Nguyen Minh Nguyet
1,2, Dinh The Trung
1,2, Vianney Tricou
1, Sutee Yoksan
3, Nguyen Minh
Dung
2, Tran Van Ngoc
2, Tran Tinh Hien
2, Jeremy Farrar
1,4, Bridget Wills
1,4, Cameron P. Simmons
1,4*
1Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam, 2Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam, 3Center
for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University, Bangkok, Thailand, 4Centre for Clinical Vaccinology
and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford, United Kingdom
Abstract
Background: Dengue is a public health problem in many countries. Rapid diagnosis of dengue can assist patient triage and
management. Detection of the dengue viral protein, NS1, represents a new approach to dengue diagnosis.
Methodology/Principal Findings: The sensitivity and specificity of the Platelia NS1 ELISA assay and an NS1 lateral flow rapid
test (LFRT) were compared against a gold standard reference diagnostic algorithm in 138 Vietnamese children and adults.
Overall, the Platelia NS1 ELISA was modestly more sensitive (82%) than the NS1 LFRT (72%) in confirmed dengue cases. Both
ELISA and LFRT assays were more sensitive for primary than secondary dengue, and for specimens collected within 3 days of
illness onset relative to later time points. The presence of measurable DENV-reactive IgG and to a lesser extent IgM in the
test sample was associated with a significantly lower rate of NS1 detection in both assays. NS1 positivity was associated with
the underlying viraemia, as NS1-positive samples had a significantly higher viraemia than NS1-negative samples matched
for duration of illness. The Platelia and NS1 LFRT were 100% specific, being negative in all febrile patients without evidence
of recent dengue, as well as in patients with enteric fever, malaria, Japanese encephalitis and leptospirosis.
Conclusions/Significance: Collectively, these data suggest NS1 assays deserve inclusion in the diagnostic evaluation of
dengue patients, but with due consideration for the limitations in patients who present late in their illness or have a
concomitant humoral immune response.
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Introduction
Dengue is a major public health problem in many parts of the
tropical developing world [1,2]. Dengue is caused by infection
with one of four serotypes of dengue virus (DENV1-4), which are
arboviruses belonging to the Flaviviridae family. Although most
DENV infections are asymptomatic, a proportion result in
clinically apparent disease that varies in severity from mild
undifferentiated fever through to more severe syndromes,
primarily dengue haemorrhagic fever (DHF) and dengue shock
syndrome (DSS). DHF is a vasculopathy characterized by capillary
leakage and haematological dysregulation; in severe case hypovo-
laemic shock (DSS) may develop. There are no licensed vaccines
or specific antiviral therapies for dengue, and patient management
relies on good supportive care.
Timely, sensitive and specific diagnosis of DENV infection can
assist in patient management. Prompt diagnosis of index cases can
also facilitate vector control activities in the community so as to
mitigate further transmission. NS1 is 55 kDa glycoprotein secreted
by DENV infected cells in vitro and in vivo. The function of NS1 in
viral replication is not well understood, other than it appears to be
essential and might serve to anchor the replication complex to the
membrane of the endoplasmic reticulum [3]. NS1 is postulated to
contribute to the pathogenesis of dengue. First, in children elevated
NS1 plasma concentrations early in illness are associated with more
severe disease, possibly reflecting higher viral burdens in these
patients [4,5]. The potential for early NS1 concentrations to predict
clinical outcomehas been postulated but notassessed [4].It hasbeen
suggested that high NS1 levels may activate complement in solution
and/or by directly binding endothelial cells, and may establish foci
for immune complex formation leading to complement activation,
endothelial damage and capillary leakage [5,6].
The availability of commercial ELISA assays to detect the
DENV NS1 protein in acute plasma provides an additional
dengue diagnostic tool to the existing approaches of PCR, serology
and, less frequently, virus isolation [7–14]. The assessment of NS1
assays as diagnostic tools across a wide range of patient
populations and viral serotypes is an important part of the process
of identifying where these assays may fit into existing dengue
diagnostic algorithms. The purpose of the current study was two-
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commercial NS1 assays, the Platelia ELISA and a lateral flow
rapid test (NS1-LFRT), in the context of different viral serotypes,
viral burdens and clinical presentations in Vietnamese patients.
Second, to assess the specificity of these NS1 assays in patients with
other confirmed infections. Our findings suggest that both the
Platelia ELISA and NS1-LFRT are specific tools for diagnosing
acute dengue, though the sensitivity of both is influenced by the
level of viraemia and host humoral immune response.
Materials and Methods
Patient enrolment
A series of prospective clinical research studies on dengue are in
progress at the Hospital for Tropical Diseases (HTD) in Ho Chi
Minh City, Viet Nam. Patients greater than 2 years of age admitted
to one of the intensive care units (adult or paediatric) or to one of the
general wards with a clinical suspicion of dengue as their primary
diagnosis are eligible for enrolment following written informed
consent by the patient or guardian. All studies have received
approval from the Ethics Committee of the HTD and from the
Oxford Tropical Research Ethics Committee. All patients in these
studies are assessed daily by a study physician and have serial
haematocrit and platelet estimations performed, as well as
appropriate sampling for diagnostic serology and virology. Other
investigations and clinical management are at the discretion of the
attending physicians. After discharge each patient is classified using
the current WHO criteria for DF, DHF and DSS. From November
2007 to January 2008, we prospectively tested consecutive acute
plasmasamples fromall children and adults enrolled inthesestudies.
Plasma samples from patients with another confirmed diagnosis
(malaria, enteric fever or leptospirosis) were obtained from stored
specimens collected as part of other prospective studies at HTD
between 2001 and 2008. The diagnosis of Plasmodium falciparum
malaria was made by blood smear. Enteric Fever was diagnosed
by blood culture of S. typhi or S paratyphi. Leptospirosis was
diagnosed by positive serology (microscopic agglutination test). All
samples tested were collected within 10 days of illness onset.
Dengue diagnostics
A capture IgM and IgG ELISA assay using DENV/JEV antigens
and mAb reagents provided by Venture Technologies (Sarawak,
Malaysia), was performed as previously described [15]. The
interpretation of primary and secondary serological responses was
based on the magnitude of IgG ELISA Units in early convalescent
plasma samples taking into account the day of illness. The cut-off in
IgG ELISA units for distinguishing primary from secondary dengue
by day of illness was calibrated using a panel of acute and early
convalescent sera from Vietnamese dengue patients that were
assayed in the laboratory of Dr Sutee Yoksan using a reference IgM
andIgGantigencaptureELISAdescribedpreviously(the‘‘AFRIMS
ELISA’’) [16].
DENV loads in plasma were measured using an internally-
controlled, serotype-specific, real-time RT-PCR assay that has
been described previously [17]. Results were expressed as cDNA
equivalents per milliliter of plasma. The dengue IgG indirect
ELISA employed uncoated wells and wells coated with recombi-
nant E proteins (Hawaii Biotech, Hawaii) (2 mg/ml). Coated and
uncoated wells were blocked with 3% bovine serum albumin for
1 hr. Twofold serial dilutions of plasma, starting at 1/100, were
added to each well for 2 hrs, then washed with PBS/Tween20.
HRP-conjugated goat anti-human IgG was then added to each
well for 2 hrs, after which wells were washed and substrate (TMB)
added. The optical density was read at 450 nm. After subtracting
the O.D obtained in uncoated wells, the endpoint titre for each
plasma sample was defined as the reciprocal of the dilution giving
an optical density of 0.3.
The NS1 Platelia and lateral flow rapid tests (NS1-LFRT) were
provided by BioRad (Hercules, CA) and were performed
according to the manufacturer’s instructions. Both NS1 tests were
performed in parallel on the same day by the same experienced
technician with freshly collected acute plasma samples from each
patient. Samples that were defined as equivocal in the NS1 Platelia
ELISA assay were repeated. If they were still equivocal they were
regarded as being negative. For the NS1-LFRT, each assay strip
was independently assessed by the technician conducting the test
and a 2
nd technician who was blind to the first assessment. During
the study, there were no examples of discordance in the
interpretation of any NS1-LFRT test. The technicians performing
and scoring the NS1-assays were blind to the reference assay
results and to any clinical information on the patients.
The reference algorithm
No single diagnostic assay can diagnose all dengue patients at the
various times they may present with symptoms. Consequently, a
diagnosis of ‘‘confirmed acute dengue’’ was reached using an
algorithm (described in Fig. S1) based on 3 assays; RT-PCR
detection of DENV RNA in plasma, and changes in DENV-
reactive IgM and IgG levels in paired plasma specimens. In brief, a
diagnosis of ‘‘lab-confirmed dengue’’ was made if there was a
clinical suspicion of dengue and, a) the RT-PCR assay was positive,
b) DENV-IgM seroconversion (i.e. from negative to positive)
occurred between paired specimens, c) levels of DENV reactive
IgM increased significantly between paired specimens and were
very high in the 2
nd sample (at least 20% increase in DENV-IgM
ELISA Units from 1
st to 2
nd sample and 2
nd sample has at least 20
ELISA Units) , d) there was a four-fold rise in IgG titre to
recombinant DENV E proteins measured in indirect ELISA in the
presence of significant DENV IgM levels or e) IgG seroconversion
was demonstrated in the IgG capture ELISA in the presence of
significant DENV IgM levels. The rationale for using two
approaches to measuring DENV-reactive IgG is two-fold. The
indirect ELISA provides a quantitative measure of IgG titres to
recombinant E proteins and is therefore able to detect four-fold
changes in IgG levels to the E protein. The IgG antigen-capture
assay provides a semi-quantitative measure of IgG levels and is best
Author Summary
Dengue is a viral infection of humans that is transmitted by
mosquitoes. Dengue is a very important public health
problem in many developing countries. Recently, new
tests to help diagnose patients with dengue have been
developed. Evaluating these tests to see how well they
perform in different countries and in different health care
settings is an important process that helps to guide health
care policy on whether these assays are likely to be useful
in making a diagnosis, and if so, when best to use them.
Our hospital-based results, using two different types of
NS1 tests for diagnosing dengue, indicates that these tests
are most sensitive when used during the first 3 days of
illness and are most likely to be positive if the patient has
primary dengue. Our results also show that a positive NS1
test result is a reflection of the amount of virus in the
blood, so that patients with high amounts of virus in the
blood are more likely to be NS1 positive. Collectively, the
results indicate these NS1 tests deserve inclusion in the
diagnostic approach to dengue.
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the context of IgG serology, a diagnosis of ‘‘lab confirmed dengue’’
is only made when the changes in acute/early convalescent IgG
levels (i.e. seroconversion or 4-fold change) occur in the presence of
detectable DENV-reactive IgM levels. This provides greater
specificity for a diagnosis of acute dengue than using IgG
measurements alone.
Statistics
All statistical analysis was performed using Intercooled STATA
version 9.2 (StataCorp, TX). Significance was assigned at P,0.05
for all parameters and were two-sided unless otherwise indicated.
Uncertainty was expressed by 95% confidence intervals. Categor-
ical variables between groups were compared by Fisher’s exact
test. The t-test was used for continuous variables.
Results
Characteristics of the study population
The baseline characteristics of the study population of the 138
cases of suspected dengue consecutively enrolled in research
studies at the HTD between November 2007 and January 2008
are shown in Table 1. The mean duration of illness prior to the test
plasma sample being collected was 3 days (range; 1–6). Patients
with a breadth of disease severities and illness durations were
represented in the study, including patients with DSS. There were
117 patients diagnosed with ‘‘acute dengue’’, and 8 cases
diagnosed as ‘‘recent dengue’’ according to the laboratory
reference algorithm. Of the ‘‘recent dengue’’ cases, 1/8 had
DHF and 7/8 had established DSS. Since the clinical picture was
so clear in these patients, and was supported by highly suggestive
serology, we included these patients in the ‘‘acute dengue’’
category, for a total of 125 acute dengue patients. There were 13
patients in whom there was no evidence of acute or recent dengue.
Overall sensitivity of NS1 tests versus reference algorithm
The sensitivity and specificity of each NS1 test was compared
against the result of the reference diagnostic algorithm in acute
plasma specimens. Samples that were equivocal in the Platelia
NS1 assays on first testing (n=2) were re-tested; one sample was
negative whilst the other remained equivocal and thereafter was
regarded as negative. Overall, the Platelia NS1 ELISA assay was
more sensitive than the NS1-LFRT test for the diagnosis of acute
dengue relative to the reference algorithm (Table 2; 83% versus
73%, P=0.047). Against RT-PCR as the reference test, the
sensitivity of the Platelia NS1 ELISA assay was greater than the
NS1-LFRT (90% versus 79%, P=0.01). There were 4 and 3
patients who were positive in the Platelia NS1 ELISA assay and
NS1-LFRT respectively who were negative in the RT-PCR. The
specificity of both tests was 100%, albeit the number of patients
who had no evidence of acute or recent dengue was small (n=13)
cases.
Sensitivity of NS1 tests by day of illness
The sensitivity of both Platelia and NS1-LFRT tests was
influenced by the patient’s duration of illness prior to study entry
(Fig. 1). Thus, both the Platelia and NS1-LFRT were significantly
more sensitive in test samples collected within 3 days of illness
onset versus those collected at later times (Table 3).
NS1 sensitivity in primary or secondary infection
In general, NS1 detection was higher in patients with primary
dengue than secondary dengue (Table 4). This difference was
statistically significant for the NS1-LFRT (P=0.01) and of
Table 1. Baseline table summarizing key clinical, viral and
demographic information on the study population.
Variable
Confirmed dengue
(n=125)
Other febrile illness
(n=13)
N (%) or Median
(range)
N (%) or Median
(range)
Male sex 56 (44.8%) 6 (46.2%)
Age (years) 16 (4–42) 12 (7–40)
Day of illness 3 (1–6) 3 (1–6)
Dengue diagnosis by:
PCR alone 11 (9%)
Serology alone
a 14 (11%)
PCR and serology 100 (80.0%)
Infecting serotype
DENV-1 63 (50.4%)
DENV-2 20 (16.0%)
DENV-3 25 (20.0%)
DENV-4 3 (2.4%)
unknown 14 (11.2%)
Clinical severity
DF 49 (39.2%)
DHFI 16 (12.8%)
DHFII 40 (32.0%)
DHFIII 20 (16.0%)
Serological status
Primary 24 (19%)
Secondary 93 (74%)
Indeterminate 8 (6%)
aincludes 8 patients who were diagnosed as ‘‘recent dengue’’ by serology but
when considered in the context of their clinical presentations were then
defined as confirmed dengue.
doi:10.1371/journal.pntd.0000360.t001
Table 2. Sensitivity and specificity, positive and negative predictive values of each NS1 assay against the gold standard algorithm.
NS1 assays
Study gp
(n=)
Acute
dengue
NS1
positive
Sensitivity %
(95% CI)
Specificity %
(95% CI)
a
PPV % (95%
CI)
a
NPV (%) (95%
CI) P value
Platelia NS1 138 125 104 83.2 (75.5–89.3) 100 (86.7–100.0) 100 (97.2–100.0) 38.2 (22.2– 56.4) 0.047
LFRT-NS1 138 125 91 72.8 (64.1–80.3) 100 (91.6–100) 100 (96.7–100) 27.6 (15.6–42.6)
aone-sided, 95% Confidence Interval.
doi:10.1371/journal.pntd.0000360.t002
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difference in sensitivity between primary and secondary dengue
was not associated with the illness day at the time of testing (primary
dengue, mean day of illness (SD)), 3.25 (0.21)) versus secondary
dengue, 3.66 (0.13), P=0.6)). Reduced sensitivity was also not
associated with viraemia levels between primary and secondary
dengue cases (log10 mean viraemia (SD), primary: 8.05 (SD:1.40)
versus secondary 7.66 (SD:1.53), P=0.2). A possible basis for
reduced sensitivityinsecondarydengue isthat NS1, along with other
viral antigens, is sequestered in immune complexes when a
substantial level of DENV-reactive IgG is present. To test this
hypothesis, we analysed NS1 detection sensitivity in the context of
DENV-reactive IgG and IgM antibody in the test sample. The
presence of measurable DENV-reactive IgG in the test sample was
associated with a significant reduction (P,0.001) in NS1 sensitivity
in both assays (Table 5). To a lesser extent, DENV-reactive IgM was
also associated with a reduction in NS1 sensitivity and was
statistically significant in the Platelia assay (P=0.03) (Table 6).
NS1 sensitivity in relation to viraemia levels
We hypothesised that plasma viremia levels would be associated
with the detection of plasma NS1, since NS1, like virions, is a
product of infected cells. Accordingly, viremia levels were
significantly higher in patients who were NS1-positive at the time
of study enrolment versus those who NS1 negative, in both the
Platelia assay (Fig. 2A) and NS1-LFRT (data not shown). When
viraemia levels were compared in patients with matched illness
lengths (3 days), viraemia levels were also significantly higher in
NS1-positive patients (Fig. 2B).
NS1 sensitivity in relation to viral serotype
The sensitivity of each NS1 assay was considered in the context
of the infecting serotype. NS1 detection was significantly reduced
in DENV-2 infected patients (55%) relative to DENV-1 (98%;
P,0.001) or DENV-3 (96%; P=0.004) infected patients in both
Platelia (Fig. 3A) and LFRT (data not shown). The reduced
sensitivity of NS1 assays for DENV-2 infected patients could in
part be related to the serological response in these individuals;
there was a statistically non-significant trend towards more
secondary dengue in patients with DENV-2 (85%) than either
DENV-1 (76%) or DENV-3 (73%) (P=0.36) and a relatively
Figure1.RelationshipbetweendayofillnessandNS1sensitivity.
Shown is percentage sensitivity of (A) Platelia ELISA and (B) LFRT assays
by day of illness in patients with confirmed dengue (n=125).
doi:10.1371/journal.pntd.0000360.g001
Table 3. Sensitivity of NS1 assays in plasma samples collected within 3 days of illness onset versus those collected at a later time.
Sample group NS1 status Platelia % (95% CI) P value
a NS1-LFR % (95% CI) P value
a
Sensitivity of NS1 #3 day (n=75) NS1 (+) 69 0.002 61 0.01
NS1 (2)6 1 4
90.6 (81.7–96.1) 80.0 (69.2–88.3)
Sensitivity of NS1 .3 day (n=50) NS1 (+)3 5 3 0
NS1 (2)1 5 2 0
70.0 (55.4–82.1) 60.0 (45.1–73.5)
aFisher’s exact test.
doi:10.1371/journal.pntd.0000360.t003
Table 4. Sensitivity of NS1 assays in patients with primary and secondary serological profiles.
Sample group NS1 status Platelia (95% CI) P value
a NS1-LFR (95% CI) P value
a
Sensitivity of NS1 in primary (n=24) NS1 (+) 23 0.07 22 0.01
NS1 (2)1 2
95.8 (78.9–99.9) 91.7 (73.0–98.9)
Sensitivity of NS1 in secondary (n=93) NS1 (+)7 3 6 1
NS1 (2)2 0 3 2
78.5 (68.8–86.3) 65.6 (55.0–75.1)
aFisher’s exact test.
doi:10.1371/journal.pntd.0000360.t004
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DENV reactive IgG (Fig. 3B), rather than IgM (Fig. 3C), in the test
sample. There was also a statistically non-significant trend toward
lower viraemia in the test samples from DENV-2 infected patients
(DENV-2 log10 mean viraemia (SD); 7.38(1.68)) versus DENV-1
(7.97(1.49)) or DENV-3 (7.79(1.47)). The reduced sensitivity of
NS1 detection in DENV-2 infected patients was not due to
significant differences in the mean duration of illness at the time of
sampling (DENV-1, mean 3.3 days; DENV-2, mean 3.4 days;
DENV-3, mean 3.3 days). In summary, NS1 detection was a
robust diagnostic test in DENV-1 and DENV-3 infections, but was
less sensitive in DENV-2 infections in part because test samples
from these patients were generally more likely to have a
concomitant DENV-IgG response, suggestive of secondary
infection, and lower viraemias, all of which are associated with
reduced NS1 detection (see Table 5 and Fig. 2B).
NS1 specificity in healthy blood donors and patients with
other confirmed diagnoses
Since the number of patients with no evidence of acute dengue
was small (n=13) in this study (Table 1), efforts were made to
assess the specificity of dengue NS1 assays in patients with other
infectious diseases whose transmission geographically overlaps
with dengue. To this end, frozen acute (within 10 days of illness
onset) plasma samples from patients with culture confirmed enteric
fever (S. Typhi, n=25 and Paratyphi, n=25), smear positive P.
falciparum malaria (n=52), serologically-proven Japanese enceph-
alitis (n=11) and leptospirosis (n=12) were tested in parallel by
both NS1 Platelia ELISA and NS1-LFRT. In all cases, NS1 tests
were negative in these samples.
Discussion
No single diagnostic assay in isolation is adequately sensitive and
specific enough to diagnose all acute cases of dengue. DENV-
specific RT-PCR is a robust test during the viraemic febrile phase,
but is less sensitive around the time of defervescence, a time when
the clinical complications of vascular leakage are most likely to
manifest. DENV IgM serology is a simple and robust approach to
diagnosis, but this method is not sensitive in the very early stages of
disease and strictly, requires paired specimens for definitive
laboratory determination. Similarly, IgG serology is not sensitive
early in the illness, requires paired specimens and lacks specificity
because of cross-reactivity with other flaviviruses. The present
study has demonstrated that NS1 detection via ELISA assay or
LFRT, particularly in the first 3 days of illness, provides a
reasonably sensitive and specific approach to dengue diagnosis in
hospitalized patients using a single specimen. Accordingly, we
have revised the dengue diagnostic algorithm used by our
laboratory to accommodate NS1 testing (Fig. S2).
Studies of the sensitivity and specificity of the Platelia ELISA
have been reported previously and, collectively, several prominent
themes are evident. First, not every acute dengue case has
measurable NS1 antigenaemia and the present study suggests that
this is a reflection of the viraemia, with NS1 negative patients
having a significantly lower mean viraemia than NS1 positive
patients with the same duration of illness history. Second,
sensitivity declines with increasing time since the onset of
symptoms and this is likely a reflection of decreasing viral burden
[7,10,13]. Third, Platelia assays are less sensitive in secondary
dengue cases [7,10] and this is consistent with our finding of
reduced sensitivity in secondary dengue cases and substantially
reduced sensitivity in test samples with a measurable level of anti-
DENV IgG. A possible explanation for reduced NS1 sensitivity in
the presence of a measurable anti-DENV antibody response is that
plasma NS1 is sequestered in immune complexes and that target
epitopes are not accessible to either the plate-bound or probe mAb
in the NS1 ELISA. Indeed, efforts to dissociate immune complexes
can enhance the sensitivity of the Platelia assay [14]. The clinical
implications of this in dengue endemic areas are subtle - patients
who present to health care facilities more than 3 days after onset of
symptoms with clinical signs of vascular leakage, haemorrhage or
even DSS may already have an established anamnestic humoral
immune response characteristic of a secondary infection and are
Table 5. Sensitivity of each NS1 assay in the presence or absence of measurable DENV-reactive IgG in the test sample.
Status
a Total NS1 Platelia NS1-LFRT Sensitivity (% ) (95% CI)
Positive Negative Positive Negative NS1 Platelia NS1-LFRT
IgG positive 38 23 15 18 20 60.5 (43.4–76.0) 47.4 (31.0–64.2)
IgG negative 87 81 6 73 14 93.1 (85.6–97.4) 83.9 (74.5–90.9)
P value P,0.001 P,0.001
aIgG in test sample.
doi:10.1371/journal.pntd.0000360.t005
Table 6. Sensitivity of each NS1 assay in the presence or absence of measurable DENV-reactive IgM in the test sample.
Status
a Total NS1 Platelia NS1-LFRT Sensitivity (% ) (95% CI)
Positive Negative Positive Negative NS1 Platelia NS1-LFRT
IgM positive 35 25 10 23 12 71.4 (53.7–85.3) 65.7 (47.8–80.9)
IgM negative 90 79 11 68 22 87.7 (79.2–93.7) 75.5 (65.4–84.0)
P value P=0.03 P=0.26
aIgM in test sample.
doi:10.1371/journal.pntd.0000360.t006
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that clinical and laboratory staff understand the limitations of
existing NS1 antigen tests and that a NS1 negative assay result does
not exclude dengue as a diagnosis. Interestingly, in this study NS1
sensitivity was substantially lower for patients with DENV-2
infections In part, this may relate to the trend for a higher
proportion of DENV-2 patients having secondary dengue and
having measurable anti-DENV IgG in the test sample. An
alternative explanation is that the affinity of the NS1-specific probe
and detector mAbs is lower for the lineage (Asian1) of DENV-2
currently circulating in Viet Nam than for DENV-1 or DENV-3;
further experiments would be required to address this hypothesis.
An assessment of the NS1-LFRT versus the Platelia ELISA has
been conducted previously in adults in French Guiana with a
reported overall sensitivity and specificity of 81% and 100%
respectively for the NS1-LFRT [7]. Unlike this previous study, we
compared the accuracy of each assay, performed in parallel on the
same day, in a group of paediatric and adult patients encompass-
ing a broad range of dengue disease severities and considered the
results in the context of viral burden and humoral immune
response. Overall, the NS1-LFRT assay was modestly less sensitive
than the Platelia NS1 ELISA in this study (73% versus 83%) but
importantly retained high specificity (100%). The attraction of the
NS1-LFRT relative to the Platelia ELISA is its ease of use and
speed (15 minutes versus 2 hrs), though this comes at a greater
cost per test (,$10 vs $5). An obvious setting in which to use this
assay format is in primary health care clinics for testing of febrile
patients presenting early in their illness. In our hospital-based
setting, the sensitivity of the NS1-LFRT was 81% in patients
admitted within 3 days of illness onset. The ongoing development
Figure 2. Viral loads by NS1 status in the Platelia ELISA at the
time of study enrolment or after 3 days of illness. Shown is the
mean (interquartile and range) viraemia level in NS1 positive and NS1
negative (Platelia ELISA) patients with a measurable viraemia (n=111)
at (A) the time of study enrolment or (B) after 3 days of illness
durations. The limit of detection of the assay is shown with a dashed
line. Viraemia levels were significantly higher in NS1 positive patients
relative to NS1 negative patients (Mann-Whitney test). The same
observations with regard to viraemia levels were made with the NS1
LFRT (data not shown).
doi:10.1371/journal.pntd.0000360.g002
Figure 3. NS1 sensitivity of the Platelia ELISA in the context of
viral serotype and humoral immune response. Shown in (A) is the
sensitivity of NS1 detection in the enrolment sample according to the
infecting serotype identified by real-time RT-PCR (results for DENV-4 not
shown as the sample size was small: n=3). NS1 detection in DENV-2
infectedpatientswassignificantlylesssensitivethanforDENV-1 orDENV-
3. The proportion of patients with detectable DENV-reactive (B) IgG or
(C) IgM antibodies (measured by capture ELISAs) in the test sample was
also related to the infecting serotype. Test samples from DENV-2 infected
patients were more likely to have measurable levels of DENV-reactive IgG
but not IgM, albeit this was not statistically significant.
doi:10.1371/journal.pntd.0000360.g003
Diagnostic Accuracy of NS1 Assays for Dengue
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accurate rapid tests, such as the NS1-LFRT even more important
since diagnosing patients quickly and early will provide the
greatest window of opportunity for an anti-viral drug to deliver a
clinical benefit.
A weakness of the current study is that relatively few of the
patients in the prospectively assessed patient population did not
have dengue. We compensated for this by including a large
number of patients with known alternative diagnoses. The
strengths of the current study, and point of difference from
published studies, are that we included patients with severe clinical
presentations and investigated the relationship between NS1
positivity, viraemia levels, illness history and Ig responses. The
finding that viraemia levels are, on average, higher in NS1-positive
patients is a novel finding in the context of these commercial
assays. The significance of this observation is tied to the widely
accepted view that early viraemia levels are associated with disease
severity [19,20]. Thus, NS1 detection may be biased towards
detecting those patients who, on average, have the highest
viraemias and with relatively higher risks of developing compli-
cations during their illness. Future studies should measure the
prognostic value of early NS1 measurements for predicting
patients at risk of developing severe complications, e.g. DSS.
Supporting Information
Figure S1 A positive result in any of the first 5 tests is sufficient
for a lab diagnosis of confirmed dengue.
Found at: doi:10.1371/journal.pntd.0000360.s001 (5.58 MB TIF)
Figure S2 Suggested place for NS1 testing in a diagnostic
algorithm approach to confirmation of dengue. A positive result in
any of the first 6 tests is sufficient for a lab diagnosis of confirmed
dengue.
Found at: doi:10.1371/journal.pntd.0000360.s002 (6.05 MB TIF)
Checklist S1 STARD checklist
Found at: doi:10.1371/journal.pntd.0000360.s003 (6.59 MB PDF)
Flowchart S1 STARD flowchart for NS1 LFRT
Found at: doi:10.1371/journal.pntd.0000360.s004 (0.03 MB
DOC)
Flowchart S2 STARD flowchart for Platelia
Found at: doi:10.1371/journal.pntd.0000360.s005 (0.03 MB
DOC)
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